Work

ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study

Year: 2004

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2004.22.14_suppl.3051

Authors: J. V. Heymach, R.-P. Dong, I. Dimery, C. Wheeler, P. Fidias, C. Lu, B. Johnson, R. Herbst

Institutions: The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, AstraZeneca (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2604494474

Cites:

Cited by: 21

Related to: 10